The Department of Psychiatry has a strong history of extramural funding, especially in the areas of schizophrenia, depression, brain stimulation, and suicide. We have received about $2,000,000 in direct cost support for our extramural research programs since the fiscal year 2013, with the strongest support coming from the NIMH.
A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight
in Young Adults with Schizophrenia, Schizoaffective, or Bipolar I Disorder Who are
Early in Their Illness
Alkermes, Inc
PI: Joseph McEvoy, M.D.
A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
NARSAD Independent Investigator Grant
PI: Brian Miller, MD, PhD, MPH
A randomized controlled trial of adjunctive siltuximab in schizophrenia.
Stanley Medical Research Institute
PI: Brian Miller, MD, PhD, MPH
Insomnia, Autonomic Dysfunction, and Suicidal Ideation in Schizophrenia
Augusta University Pilot Study Research Program
PI: Brian Miller, MD, PhD, MPH
Improving cognition via exercise in schizophrenia
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, MD
A multicenter, randomized, controlled trial of Brexpiprazole for the treatment of
co-occurring schizophrenia and substance use disorder
Otsuka Pharmaceuticals
PI: Joseph McEvoy, MD
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, MD
Observational Study of LAIs in Schizophrenia
Alkermes, Inc
PI: Joseph McEvoy, M.D.
Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate
the safety and efficacy of BIIB104 in subjects with cognitive impairment associated
with schizophrenia
Biogen MA, Inc.
PI: Joseph McEvoy, MD
A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
NARSAD Independent Investigator Grant
PI: Brian Miller, MD, PhD, MPH
A randomized controlled trial of adjunctive siltuximab in schizophrenia.
Stanley Medical Research Institute
PI: Brian Miller, MD, PhD, MPH
Clozapine, Insomnia, Hyperarousal, and Suicide in Schizophrenia
Augusta University Pilot Study Research Program
PI: Brian Miller, MD, PhD, MPH
A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy,
safety, and tolerability of orally administered BI 409306 during a 52-week treatment
period as an early intervention in patients with attenuated psychosis syndrome.
Boehringer Ingelheim Pharmaceuticals, Inc.
PI: Joseph McEvoy, MD
Improving cognition via exercise in schizophrenia
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, MD
Metformin and Lorcaserin for weight loss in people with schizophrenia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
PI: Joseph McEvoy, MD
A phase II, 12-week, randomized, double-blind, placebo-controlled, parallel study
to evaluate efficacy, safety, tolerability, and pharmacokinetics of the three dose
levels of TAK-831 in adjunctive treatment of adult patients with negative symptoms
of schizophrenia
Millennium Pharmaceuticals, Inc.
PI: Joseph McEvoy, MD
Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate
the safety and efficacy of BIIB104 in subjects with cognitive impairment associated
with schizophrenia
Biogen MA, Inc.
PI: Joseph McEvoy, MD
Pilot studies of pupillometry in suicidal and non-suicidal patients
Augusta University
PI: W. Vaughn McCall, MD
Co-investigator: Peter B. Rosenquist, MD and Brian Miller, MD, Ph.D., MPH
A randomized double-blind feasibility study comparing mood and cognitive outcomes
for depressed patients treated with transcranial magnetic stimulation (TMS) combined
with Lumosity cognitive exercises vs. computer game control task.
PI: Peter B. Rosenquist, MD
The use of paired pulse TMS measures to assess drug effects on Neuronal Excitability
in Amyotrophic Lateral Sclerosis.
PI: Peter B. Rosenquist, MD
The Randomised Controlled Trial of Frontoparietal and Temporoparietal Electroconvulsive
Therapy (ECT) for Severe Depression: The RAFT ECT Study
Augusta University
PI: W. Vaughn McCall, MD
Focal Electrically-Administered Seizure Therapy (FEAST) (2-site study)
Mecta Corporation (ClinicalTrials.gov Identifier: NCT02535572)
PI: W. Vaughn McCall, MD
RECOVER: A Prospective, Multi-Center, Randomized Controlled Blinded Trial Demonstrating
the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a
No Stimulation Control in Subjects with Treatment- Resistant Depression
Augusta University
PI: Peter B. Rosenquist, MD
Co-Investigator: W. Vaughn McCall, MD., MS
Training Psychiatrists, Nurse Practitioners, and Psychologist to Work Collaboratively
to Address Rural Behavioral Health Disparities
Health Resources and Services Administration
Behavioral Health Workforce Education and Training Program
PI: Jean Pawl
Coinvestigator and Course Director: Peter Rosenquist, MD
Measuring Time-Dependent Pupillary Light Reflex Variables
PI: W. Vaughn McCall, MD
Inflammation and the Metabolic Syndrome in Psychosis
National Institute of Mental Health
PI: Brian Miller, MD, PhD, MPH
Assessment and outcomes monitoring in psychiatric clinical practice.
PI: Peter B. Rosenquist, MD
Screening for clozapine-induced myocarditis-A naturalistic observation study.
PI: Sandarsh Surya, MBBS and Joseph McEvoy, MD
Double-blind, Placebo-controlled, Phase 2 trial to test efficacy and safety of AV-1-1
(L-4-chlorokynurenine) as adjunct to current antidepressant therapy in patients with
major depressive disorder (MDD) with an inadequate response to current antidepressants
VistaGen Therapeutics, Inc.
PI: W. Vaughn McCall, MD
GRISAT Educational Grant (GRU Interprofessional Substance Abuse Training for Health
Professions (GRISAT)
SAMHSA
PI: W. Vaughn McCall, MD
